MREO: Class Action Alert – Don’t Miss Key Deadlines!

Company Overview and Class Action Context

Mereo BioPharma Group plc (NASDAQ: MREO) is a UK-based clinical-stage biotech focused on rare diseases. Its lead programs have included setrusumab (UX143) for brittle bone disease (osteogenesis imperfecta, OI) and alvelestat for alpha-1 antitrypsin deficiency lung disease (www.mereobiopharma.com) (www.mereobiopharma.com). In late 2025, Mereo announced that two Phase 3 trials (ORBIT and COSMIC) of setrusumab in OI failed to meet their primary endpoints of reducing fracture rates (www.mereobiopharma.com) (www.genengnews.com). The trials did show significant gains in bone mineral density, but not enough fracture reduction for statistical significance (www.mereobiopharma.com) (www.genengnews.com). This negative outcome triggered an 87–88% collapse in MREO’s share price (from $2.31 on Dec 26, 2025 to about $0.29 on Dec 29) (www.globenewswire.com) (www.genengnews.com), wiping out much of the company’s market value. Several shareholder class action lawsuits were promptly filed, alleging that Mereo’s management had made “overwhelmingly positive” but misleading statements about the trials’ prospects while concealing adverse facts (www.globenewswire.com). The class period under these suits is June 5, 2023 to Dec 26, 2025 (spanning earlier upbeat interim data releases (ir.ultragenyx.com) through the crash), and shareholders in that window have until April 6, 2026 to seek lead plaintiff status (www.globenewswire.com). These legal actions underscore investor concern about potential misrepresentation and form a key backdrop as we evaluate MREO’s fundamentals and outlook.

Dividend Policy and Yield

Mereo BioPharma does not pay any dividends and has no history of doing so. As a development-stage biotech with recurring losses, the company has “never paid or declared any cash dividends on its ordinary shares, and does not anticipate” paying dividends in the foreseeable future (www.sec.gov). This is typical for clinical biotechs, which prioritize funding R&D over shareholder payouts. MREO’s forward dividend yield is 0.00% (www.gurufocus.com), reflecting the absence of any dividend program. Investors seeking income should note that all returns on MREO must come from capital appreciation (or depreciation), not dividends.

AFFO/FFO: Metrics like Funds From Operations (FFO) or Adjusted FFO are not applicable here, as those are used in real estate or cash-flowing businesses. Mereo has negative earnings and cash flow, so traditional cash yield measures do not apply. Instead, the company’s “funds from operations” are essentially its cash burn rate, which we discuss under leverage and runway rather than any FFO-based payout ratio.

Leverage and Debt Maturities

Mereo operates with minimal leverage, relying mainly on equity financing and partnership capital. The company carries virtually no long-term bank debt on its balance sheet (www.mereobiopharma.com) (media.mereobiopharma.com). As of September 30, 2025, Mereo had cash and equivalents of $48.7 million and total current liabilities of ~$13.8 million (www.mereobiopharma.com) (media.mereobiopharma.com). The only notable debt was a convertible loan note owed to Novartis (related to Mereo’s 2015 acquisition of setrusumab) (www.sec.gov) (www.sec.gov). This note, originally ~$5 million, had its maturity extended to February 10, 2025 at a 9% interest rate (www.sec.gov) (www.sec.gov). By year-end 2024 the note’s carrying value was about $5.5 million (classified as current liability) (media.mereobiopharma.com). In early 2025, Novartis exercised some associated warrants (purchasing ~289,922 ADS for $0.5 million) (www.sec.gov), and the loan’s maturity arrived. Mereo has since addressed this obligation, either via repayment or conversion, such that no significant debt remained by 2025’s end (the company has not indicated any outstanding loans post-maturity). Aside from the Novartis note (now resolved), Mereo’s liabilities consist mostly of accounts payables, accrued expenses, and lease obligations – none of which represent large, long-term debt burdens.

In summary, MREO’s leverage is low, which is a positive in terms of financial risk – there are no looming debt maturities that threaten solvency. This also means, however, that the company’s operations are funded by its cash reserves and future capital raises rather than debt. Investors should monitor the cash runway closely, as Mereo will likely seek additional equity or partner funding when needed instead of taking on debt.

Coverage and Cash Runway

Traditional coverage ratios (like interest coverage or fixed-charge coverage) are not meaningful for Mereo right now. The reason is straightforward – Mereo has no positive earnings or EBITDA to “cover” fixed charges. The company’s operating losses far exceed any interest expense. For perspective, net loss in 2024 was $43.3 million (media.mereobiopharma.com), while interest expense was relatively small (about $1.2 million in 2024, mostly from the Novartis note) (www.sec.gov). With negative EBIT, metrics such as EBIT/Interest are negative; effectively, Mereo’s interest coverage is nil because it relies on its cash reserves (and occasional interest income) to meet obligations (media.mereobiopharma.com).

A more relevant “coverage” for a biotech is cash coverage of its R&D and overhead – i.e. how long the cash on hand can cover the company’s burn rate. On this front, Mereo’s management had previously guided that existing cash would fund operations into 2027 (www.mereobiopharma.com). After the setrusumab trial failure, the company implemented cost cuts (notably halting pre-commercial manufacturing spend for setrusumab) and confirmed it had about $41 million in cash at December 31, 2025 (www.biospace.com). This led to an updated runway guidance through mid-2027 under current plans (www.biospace.com). In other words, at the start of 2026 Mereo has roughly 1.5+ years of cash coverage for its ongoing expenses (assuming no revenue inflows). This runway could be extended or shortened depending on any new trials or partnerships. It’s worth noting that the cash guidance excludes any potential milestone payments from a future alvelestat partnership or monetization of non-core programs (www.mereobiopharma.com). Overall, Mereo appears to have enough cash to cover its operations for the next ~18 months without needing to tap capital markets immediately – a comforting sign, though this assumes the company refrains from launching major new trials on its own.

Valuation and Comparables

Valuing a pre-revenue biotech like Mereo is challenging using conventional metrics. The company has no earnings (P/E is not meaningful) and no FFO/AFFO as a REIT would. Instead, investors value MREO based on its pipeline prospects, partnerships, and cash. Following the Phase 3 failure, the market is essentially pricing Mereo primarily on its cash balance and the potential of its remaining assets. At an ADS price of around $0.50 in early 2026 (post-crash rebound) (www.genengnews.com), Mereo’s market capitalization is roughly ~$80 million (with ~159 million ADS outstanding, each 5 ordinary shares) (www.mereobiopharma.com). This is on the order of 2 times its cash on hand (~$41M cash at end of 2025) (www.biospace.com), implying an enterprise value (EV) of only ~$39 million. In other words, the market is assigning a modest ~$30–40M value to Mereo’s entire drug pipeline and intellectual property beyond its cash.

For context, before the trial results, MREO was trading at $2+ per share, giving it a market cap near $350 million. The 87% share price collapse in late December obliterated approximately $280 million in market value (www.globenewswire.com). That drop corresponds to investors effectively writing off the value of setrusumab after the failed trials. Indeed, analysts noted that the Street would “largely remove [setrusumab] from their valuations” going forward (www.genengnews.com). Comparatively, Mereo’s partner Ultragenyx (NASDAQ: RARE) – a much larger biotech – saw its stock fall ~42% (from ~$34 to ~$20) on the news (www.genengnews.com), reflecting disappointment, though Ultragenyx’s diversified portfolio helped it recover some losses shortly thereafter.

In absence of earnings or revenue multiples, one crude way to assess Mereo’s valuation is price-to-book or price-to-cash. MREO currently trades at approximately 1.1–1.3x its net cash – a level suggesting skepticism about the pipeline but not a complete abandonment. Many small biotechs with a single Phase 3–ready asset trade near cash value if prospects are uncertain. Mereo’s ~$80M market cap likely reflects: (1) the remaining option value of alvelestat, which is Phase 3–ready and has orphan drug status (media.mereobiopharma.com), and (2) the possibility that some subset or re-analysis of setrusumab data could retain value (for example, maybe in younger patients or with a different endpoint). If either of these catalysts turns positive – such as securing a partnership deal for alvelestat or finding a path forward for setrusumab – MREO’s valuation could improve from these depressed levels. Conversely, absent new developments, the stock may continue to languish around cash value, or even drift below cash if the market anticipates cash burn without clear progress. Essentially, Mereo is now valued like an early-stage biotech with one late-stage asset (alvelestat) plus cash, after having lost the market premium for its OI program.

Key Risks and Red Flags

Mereo BioPharma is a high-risk, speculative stock at this stage, with several notable risks and red flags for investors:

– Clinical and Regulatory Risk: Mereo’s prospects hinge on drug development success, yet its lead program just suffered a major failure. The company itself has acknowledged it “depends heavily on the success of setrusumab and alvelestat” and cannot assure any will achieve regulatory approval (www.sec.gov). The failure of setrusumab’s Phase 3 trials is a huge setback. There is no guarantee that further analysis will rescue the program or that regulators will accept secondary endpoints like bone density as sufficient for approval. Likewise, alvelestat must still prove itself in a Phase 3 trial that hasn’t started; any trial delays or subpar results there would compound the risk.

– Legal and Management Credibility: The stock is now under the shadow of shareholder class action lawsuits. The lawsuit alleges that management painted an overly rosy picture of the OI trials while hiding material problems (www.globenewswire.com). If evidence supports these claims, it suggests potential governance issues or at least overly aggressive communications. Regardless of the outcome in court, the situation is a red flag for investor trust. The class action also poses a financial risk (albeit likely covered by insurance to an extent) and may distract management. Key deadline: Investors who incurred losses during June 2023–Dec 2025 should note the April 6, 2026 lead plaintiff deadline (www.globenewswire.com) if they wish to participate in the case. The overhang of litigation and possible settlement costs will linger until resolved.

– Share Price and Listing Concerns: After the collapse, MREO shares are trading in penny-stock territory (well under $1). This raises the risk of Nasdaq compliance issues – Nasdaq generally requires a minimum $1 bid price. Should the stock remain below $1 for an extended period, Mereo could receive a deficiency notice and eventually face delisting if it doesn’t regain compliance (often companies in this situation resort to reverse stock splits to cure the deficiency). The low share price also reflects low market confidence and may limit the stock’s appeal to institutional investors (some of whom cannot hold stocks <$5 or <$1). In short, the company’s market perception is at a low ebb, which can be self-reinforcing.

– Financing and Dilution Risk: While Mereo has sufficient cash for now, its cash burn (net loss of $43M in 2024 (media.mereobiopharma.com)) means it will need more capital in the future unless a revenue source appears. If no partnership or other non-dilutive funding comes through, Mereo would likely raise money by issuing equity or equity-linked securities. Given the depressed share price, any sizeable equity raise would be highly dilutive to existing shareholders. Past financing deals (e.g. private placement notes and warrants) have already expanded the share count (www.sec.gov) (www.sec.gov). Investors should be prepared for potential dilution ahead, especially if a costly Phase 3 trial for alvelestat must be funded.

– Strategic and Governance Overhang: There have been signs of shareholder discontent in Mereo’s recent history. In 2022, an activist investor (Rubric Capital) publicly challenged Mereo’s strategic direction and proposed new board members (www.globenewswire.com). While that proxy tussle was resolved with Mereo reiterating a strategy (and extending its cash runway via cost cuts) (www.globenewswire.com), the episode highlights governance red flags. It suggests that some large shareholders were unhappy with management’s performance and capital allocation even before the latest trial failure. Now, with the stock at fraction of its former value, the company could face renewed pressure to shake up its strategy, management, or even consider strategic alternatives (like a merger or asset sale). Such uncertainty in direction is an ongoing risk factor.

– Pipeline Concentration and Competition: Mereo is essentially down to one major development effort (alvelestat) assuming setrusumab remains stalled. This lack of diversification means the company’s fate rests on a single program’s success. Meanwhile, the areas it operates in have competitive and scientific risks: for OI, other approaches (e.g. gene therapies or other antibodies) could emerge in the long run, and for alpha-1 antitrypsin deficiency, there are existing therapies (protein augmentation) and other companies exploring novel treatments. Any advances by competitors could further erode the perceived value of Mereo’s assets.

In summary, investors should approach MREO with caution. The stock’s implosion in December 2025 is a stark reminder of the binary risk in biotech trials. Key red flags include the outcome of the class action (and what it says about management’s transparency), the urgent need to rebuild pipeline credibility, and the potential for future dilution or corporate actions. These risks need to be weighed against the remaining opportunities in Mereo’s pipeline.

Open Questions and What to Watch

Looking ahead, several open questions will determine Mereo’s trajectory:

– Can Setrusumab Be Salvaged or Repurposed? Mereo and its partner Ultragenyx are conducting additional analyses of the ORBIT and COSMIC data to determine if there’s any path forward (www.mereobiopharma.com) (www.biospace.com). For example, in the younger COSMIC trial population (ages 2–6), there was a trend of fracture reduction alongside improved bone density, though not statistically significant (www.biospace.com). Will regulators consider a subset analysis or secondary endpoints as a basis for something like an accelerated approval or a new trial design? Mereo’s team has indicated they will assess the “totality of the data” and possibly engage regulators on next steps (www.biospace.com) (www.biospace.com). An open question is whether Ultragenyx will remain committed – the partner said it would implement “significant expense reductions” after the failure (www.genengnews.com), suggesting a pullback. If Ultragenyx decides to discontinue the program, Mereo alone might lack the resources to continue setrusumab development. Watch for any announcements of regulatory meetings, subset data presentations, or a formal discontinuation of the program. Notably, no other approved treatments for OI exist (www.biospace.com), so there is still an unmet need that could justify further attempts if some efficacy signal can be found.

– Will Mereo Secure a Partner or Buyer for Alvelestat? Alvelestat (MPH-966) is Mereo’s next big hope – a Phase 3–ready drug for alpha-1 antitrypsin deficiency lung disease. The company has been actively seeking partners to co-develop or license alvelestat (media.mereobiopharma.com). This is critical because conducting a global Phase 3 trial will be expensive and Mereo’s cash, while sufficient for now, would be stretched by a full Phase 3 program. A partnership could bring upfront cash or cost-sharing that extends Mereo’s runway and validates the drug’s potential. Open question: Can Mereo ink a deal in 2026? The fact that alvelestat has orphan designation in both the EU and US (media.mereobiopharma.com) makes it more attractive, but the partner will likely review Phase 2 data closely. If a partnership or licensing deal is announced, it would be a positive catalyst for the stock. Conversely, if months go by with no deal, the market may assume Mereo will have to dilute shareholders to fund the trial on its own – or that the asset might not be as appealing as hoped. Keep an eye on industry conferences or updates; Mereo’s CEO presented at the J.P. Morgan Healthcare Conference in Jan 2026, possibly to stir interest (www.biospace.com).

– How Will the Class Action and Legal Issues Resolve? While these lawsuits can take years, any indication of the strength of the case (e.g., if a judge allows it to proceed past initial motions) or an early settlement could be noteworthy. A prolonged legal battle could slightly drain resources (time and money), though typically companies have insurance for securities litigation. The larger question is reputation – will discovery in the case reveal any concerning communications or will Mereo’s management be cleared of serious wrongdoing? The outcome may influence shareholder confidence or even the willingness of partners to collaborate. It’s an open question whether the class action results in a material payout (which could modestly impact the balance sheet) or simply fades out. Investors should at least mark the April 6, 2026 deadline and any subsequent court developments as happenings to watch.

– Is a Strategic Transaction on the Table? With MREO’s market cap so low, one must ask if the company could become a takeover target or consider merging. Larger pharma or biotech companies looking for cheap assets might be interested in alvelestat or even the OI program (despite its setback) if they believe they can design a successful trial. Alternatively, frustrated large shareholders might push for strategic alternatives. Mereo’s prior activist pressure in 2022 hints that investors won’t stay passive if value remains depressed (www.globenewswire.com). An open question is whether Mereo will choose to spin off or sell any programs (for instance, its earlier-stage oncology asset etigilimab was already deprioritized (www.mereobiopharma.com)), or even sell the whole company. No such moves have been announced, but given the circumstances, strategic discussions could be happening behind the scenes. Any hint of M&A speculation or actual offers would significantly impact the stock.

– Will the Stock Regain Compliance and Investor Interest? Mereo’s ability to stay listed on Nasdaq may force some action if the price doesn’t recover above $1. Management might have to propose a reverse stock split in 2026 to cure the price deficiency – a common move that technically boosts the share price by reducing share count. Such a step could be a double-edged sword: it keeps the listing, but historically reverse splits sometimes precede further declines if not accompanied by fundamental improvements. Another open question is whether the investor sentiment can improve: for instance, if Mereo delivers positive news (partnering, a new analysis, etc.), can it attract back institutional investors or analysts? Currently, coverage may be minimal, but a high-profile deal or data presentation could put MREO back on radar. Insider or institutional moves are also worth watching – any significant insider buys or a notable investor accumulating shares would signal confidence amid the gloom.

In conclusion, Mereo BioPharma faces a pivotal period in 2026. The company is working to regroup after a major trial failure, with its fate resting on strategic decisions in the coming months. Investors should monitor the developments around setrusumab’s post-hoc analyses, any progress with alvelestat partnerships, and how the class action/legal matters unfold. The stock’s extremely depressed valuation could either be a long-shot turnaround opportunity if Mereo executes well (or becomes a takeover target), or it could be a value trap if no positive catalysts materialize and cash eventually dwindles. With the information known so far, the coming deadlines – both legal and operational – will be key to watch, and due diligence is more important than ever for those considering positions in MREO. Any prospective investor should stay tuned to company announcements and filings, as the situation remains fluid and high-risk.

Sources: Mereo BioPharma SEC filings and press releases; GlobeNewswire class action notices; Genengnews and BioSpace reports on trial results and corporate updates (www.globenewswire.com) (www.mereobiopharma.com) (www.genengnews.com) (www.biospace.com) (www.genengnews.com) (media.mereobiopharma.com) (www.gurufocus.com) (www.globenewswire.com) (www.sec.gov). Each source has been cited inline above for specific factual references.

For informational purposes only; not investment advice.